Abstract
Background Disorders affecting the spinal cord (myelopathies) can cause severe disability. Despite diagnostic advances, approximately 12-18% of myelopathy cases continue to elude an etiological diagnosis, hampering effective treatment.
Methods This retrospective, multicenter, tertiary care cohort study conducted from 2014 to 2025 evaluated archived biofluids from patients with IM, known autoimmune myelitis, or other neurological diseases (ONDs). Proteome-wide phage display was used to discover novel autoantibodies. Targeted immunoassays were used to screen for a candidate autoantibody. Downstream metabolites were measured in the cerebrospinal fluid (CSF).
Results Autoantibodies targeting the transcobalamin receptor (CD320) responsible for cellular transport of vitamin B12 were identified in 18 out of 32 IM patients (56%) in a discovery cohort. Bioactive B12 concentration was decreased in the CSF of anti-CD320 positive patients compared to OND controls (P = 0.0273), indicative of autoimmune B12 central deficiency (ABCD). Compared to anti-CD320 negative IM cases, anti-CD320 positive IM cases demonstrated a higher frequency of subacute time course (56% vs 7%, P = 0.008), normal CSF profile (83% vs 50%, P = 0.044), and dorsolateral spinal cord abnormalities on magnetic resonance imaging (MRI) (61% vs 7%, P = 0.003). In two independent validation cohorts comprising 94 and 25 patients with IM, anti-CD320 was detected in 43 (46%) and 12 (48%) patients, respectively. Comorbid anti-CD320 was detected in a smaller proportion of patients with other known autoimmune etiologies of myelopathy. Five anti-CD320 positive IM patients received B12 supplementation with or without concurrent immunosuppression, and four out of five clinically improved.
Conclusions ABCD is associated with a substantial proportion of IM. Screening for anti-CD320 followed by metabolic confirmation of a CNS-restricted B12 deficiency may be considered in the diagnostic evaluation of myelopathy.
Competing Interest Statement
J.V.P., J.L.D., S.J.P., and M.R.W. are coinventors on a patent application related to this work (PCT/US2024/018105, Compositions and methods related to transcobalamin receptor autoantibodies). M.R.W. receives unrelated research grant funding from Roche/Genentech, Novartis, and Kyverna Therapeutics and is a founder and board member of Delve Bio Inc. He has done consulting for Pfizer, Vertex Pharmaceuticals, Ouro Medicines, and Indapta Therapeutics.
Funding Statement
This work was supported by NINDS (U01NS120836 to M.R.W., S.J.P., J.M.G., A.J.G.; R35NS111644 to S.L.H and M.R.W.; RM1NS138808 to S.J.P., M.R.W., J.L.D.; UE5NS070680 to J.V.P.; K08NS142575 to J.V.P.), the Westridge Foundation (to M.R.W. and A.J.G.), the Burroughs Wellcome Fund (to J.V.P.), and Arc Institute (to J.V.P.). The ORIGINS study is supported by NIH/NINDS (R35NS111644), NMSS (SI-2001-35701), and the Valhalla Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of California, San Francisco, IRB# 13-12236; Comite D Etica D Investigacio Amb Medicaments Girona, #1090/2015; Johns Hopkins Myelitis and Myelopathy Center, IRB# NA-00003551; Fondazione Istituto Neurologico Nazionale C. Mondino, PV-220333
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
